News und Analysen

Johnson & Johnson (NYSE: JNJ) has focused more on growth initiatives since spinning off its consumer healthcare business into what is now Kenvue. In 2022, it made a big move with the acquisition of

Johnson & Johnson (NYSE: JNJ) has focused more on growth initiatives since spinning off its consumer healthcare business into what is now Kenvue. In 2022, it made a big move with the acquisition of

Pfizer (NYSE: PFE) stock has been struggling for a while now. In the past 12 months, it has declined by 36%. A lack of growth recently, a dependence on acquisitions, and many question marks have

Pfizer (NYSE: PFE) stock has been struggling for a while now. In the past 12 months, it has declined by 36%. A lack of growth recently, a dependence on acquisitions, and many question marks have

Biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) looks unstoppable. In the past six months, the company launched a brand-new and highly promising product on the market and delivered positive

Biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) looks unstoppable. In the past six months, the company launched a brand-new and highly promising product on the market and delivered positive

Biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) looks unstoppable. In the past six months, the company launched a brand-new and highly promising product on the market and delivered positive

CRISPR Therapeutics (NASDAQ: CRSP) and Viking Therapeutics (NASDAQ: VKTX) are among the hottest mid-cap biotechs on the market. Both have delivered incredible progress in recent months, be it on the

Later this year, the Federal Reserve is projected to begin reducing interest rates. While the exact number of rate cuts is still uncertain, this regulatory action is expected to stimulate a surge in

Later this year, the Federal Reserve is projected to begin reducing interest rates. While the exact number of rate cuts is still uncertain, this regulatory action is expected to stimulate a surge in

One of the hottest themes in the pharmaceutical industry right now is weight loss. Medications specifically approved for weight loss, such as Wegovy and Zepbound, are taking the industry by storm.

One of the hottest themes in the pharmaceutical industry right now is weight loss. Medications specifically approved for weight loss, such as Wegovy and Zepbound, are taking the industry by storm.

If there were a hedge fund manager hall of fame, Ken Griffin would be a no-brainer inductee. His skillful leadership of Citadel made it one of the most successful hedge funds ever. It also made

If there were a hedge fund manager hall of fame, Ken Griffin would be a no-brainer inductee. His skillful leadership of Citadel made it one of the most successful hedge funds ever. It also made

If you're building a stream of dividend income to fuel your retirement dreams, it helps to fill your portfolio with businesses that can keep growing through a wide range of economic conditions

Earnings season, which is fast approaching, is often somewhat volatile for the stock market. Companies that overdeliver or fail to deliver can see their share prices move significantly overnight.

Earnings season, which is fast approaching, is often somewhat volatile for the stock market. Companies that overdeliver or fail to deliver can see their share prices move significantly overnight.

Viking Therapeutics (NASDAQ: VKTX) has shown its strengths from a potential product perspective and an investment perspective in recent times. The company reported excellent data from clinical

Two adages capture the dilemma investors face when they consider buying a beaten-down stock:

These well-known sayings seem to be contradictory. However, they're not when taken in the correct

Two adages capture the dilemma investors face when they consider buying a beaten-down stock:

These well-known sayings seem to be contradictory. However, they're not when taken in the correct

Dividends can provide a steady stream of income to shareholders, but only if the dividend-paying company maintains or increases its payouts over the years. Unfortunately, not every dividend payer is

The past nine months have been rough ones to be an Agenus (NASDAQ: AGEN) shareholder. The stock has collapsed by about 75% from the peak it set last June.

Investment bank analysts on Wall Street who

Microsoft (NASDAQ: MSFT) is currently the only company worth over $3 trillion. That makes it the most heavily weighted stock in both the S&P 500 and the Nasdaq Composite, but not the Dow Jones